ANTYA Investments

ANTYA Investments Inc., regulated by the Ontario Securities Commission, is registered to provide wealth management services in Canada. ANTYA manages institutional, and high net-worth client portfolios on a discretionary basis. Our investment philosophy embraces a Core-Satellite approach.  The core of the portfolio is chosen from a group of fifteen asset classes. A few stock specific asymmetrical investment opportunities comprise the satellite segment. ANTYA invests only in global, large capitalization, and investment grade companies.  

Investing That Empowers You

Bristol-Myers Beats the Drum for Celgene in 4Q18 Earnings Call

Bristol Myers Squib & Celgene–Starboard Objections Addressed Today- Successful Deal Closure Probable

Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated

Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs

We Are Buying This Large Cap Biotechnology Company After Trump's Election Win

Actionable Insights, Assured Alpha, ANTYA Investments

Actionable Insights, Assured Alpha

Event-Driven

<p>The management of <a href="https://www.smartkarma.com/entities/1133" target="_blank" data-smartkarma-citation="entities:1133:1">Bristol Myers Squibb Co (BMY US)</a> reiterated its optimistic view regarding the acquisition of <a href="https://www.smartkarma.com/entities/7410" target="_blank" data-smartkarma-citation="entities:7410:1">Celgene Corp (CELG US)</a> on its Q4-18 earnings conference call today. Unlike most acquisitions that succeed based on cost cuts or revenue synergies, Celgene’s distressed valuation allowed BMY to swoop in and buy a leading bio-tech at a bargain price: if the pipeline succeeds. We are betting it will. If not, the robust cash flows from Revlimid make it a low-risk , low-return deal.  </p>

The management of Bristol Myers Squibb Co (BMY US) reiterated its optimistic view regarding the acquisition of Celgene Corp (CELG US) on its Q4-18 earnings conference call today. Unlike most acquisitions that succeed based on cost cuts or revenue synergies, Celgene’s distressed valuation allowed BMY to swoop in and buy a leading bio-tech at a bargain price: if the pipeline succeeds. We are betting it will. If not, the robust cash flows from Revlimid make it a low-risk , low-return deal.  

ブリストル・マイヤーズスクイブ社 – セルジーン社に関する見解を再確認